[
  {
    "ts": "2025-12-24T03:10:24+00:00",
    "headline": "How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors",
    "summary": "Earlier this week, CRISPR Therapeutics reported encouraging early-stage clinical data for its allogeneic CD19 CAR T therapy, zugo-cel, in aggressive B-cell lymphoma and autoimmune diseases, and disclosed a new collaboration with Eli Lilly to test zugo-cel alongside pirtobrutinib. By pairing strong initial response rates and a favorable safety profile with Lilly’s kinase inhibitor, CRISPR Therapeutics is broadening zugo-cel’s potential role across both oncology and autoimmune...",
    "url": "https://finance.yahoo.com/news/early-zugo-cel-data-lilly-031024162.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e7b323ac-4b41-316a-8559-4c67222cb9ee",
      "content": {
        "id": "e7b323ac-4b41-316a-8559-4c67222cb9ee",
        "contentType": "STORY",
        "title": "How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors",
        "description": "",
        "summary": "Earlier this week, CRISPR Therapeutics reported encouraging early-stage clinical data for its allogeneic CD19 CAR T therapy, zugo-cel, in aggressive B-cell lymphoma and autoimmune diseases, and disclosed a new collaboration with Eli Lilly to test zugo-cel alongside pirtobrutinib. By pairing strong initial response rates and a favorable safety profile with Lilly’s kinase inhibitor, CRISPR Therapeutics is broadening zugo-cel’s potential role across both oncology and autoimmune...",
        "pubDate": "2025-12-24T03:10:24Z",
        "displayTime": "2025-12-24T03:10:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/early-zugo-cel-data-lilly-031024162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/early-zugo-cel-data-lilly-031024162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T02:00:00+00:00",
    "headline": "The U.S. Offered Putin’s Closest Ally Sanctions Relief—and a Weight-Loss Drug",
    "summary": "Engaging one of the world’s most repressive regimes, Trump envoy bonded with Belarusian dictator over Zepbound and obtained the release of hundreds of prisoners.",
    "url": "https://www.wsj.com/world/belarus-lukashenko-obesity-drug-02941fb3?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "0cf99f11-7227-3016-8e09-bca101da013a",
      "content": {
        "id": "0cf99f11-7227-3016-8e09-bca101da013a",
        "contentType": "STORY",
        "title": "The U.S. Offered Putin’s Closest Ally Sanctions Relief—and a Weight-Loss Drug",
        "description": "",
        "summary": "Engaging one of the world’s most repressive regimes, Trump envoy bonded with Belarusian dictator over Zepbound and obtained the release of hundreds of prisoners.",
        "pubDate": "2025-12-24T02:00:00Z",
        "displayTime": "2025-12-24T02:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0cf99f11-7227-3016-8e09-bca101da013a/the-u-s-offered-putin%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/204cca0e1b7ff28a21bf740202199f64",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.eqtw2a_GbiE27pkvgbeaQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/204cca0e1b7ff28a21bf740202199f64.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9IjMtJVxp.BdprSpKEy_9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/204cca0e1b7ff28a21bf740202199f64.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/world/belarus-lukashenko-obesity-drug-02941fb3?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "META"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T11:37:56+00:00",
    "headline": "3 Stocks That Investors Might Be Undervaluing By Up To 32.3%",
    "summary": "As the S&P 500 closes at a record high, buoyed by stronger-than-expected economic growth and a tech stock rally, investors are keenly observing which sectors might lead the market next year. Amidst this optimistic environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for those looking to capitalize on market inefficiencies.",
    "url": "https://finance.yahoo.com/news/3-stocks-investors-might-undervaluing-113756614.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "32ff7c57-3c10-38da-bfb6-75d922b27898",
      "content": {
        "id": "32ff7c57-3c10-38da-bfb6-75d922b27898",
        "contentType": "STORY",
        "title": "3 Stocks That Investors Might Be Undervaluing By Up To 32.3%",
        "description": "",
        "summary": "As the S&P 500 closes at a record high, buoyed by stronger-than-expected economic growth and a tech stock rally, investors are keenly observing which sectors might lead the market next year. Amidst this optimistic environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for those looking to capitalize on market inefficiencies.",
        "pubDate": "2025-12-24T11:37:56Z",
        "displayTime": "2025-12-24T11:37:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-stocks-investors-might-undervaluing-113756614.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-stocks-investors-might-undervaluing-113756614.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VRT"
            },
            {
              "symbol": "CWBC"
            },
            {
              "symbol": "CLFD"
            },
            {
              "symbol": "UMBF"
            },
            {
              "symbol": "SRAD"
            },
            {
              "symbol": "SMA"
            },
            {
              "symbol": "FLY"
            },
            {
              "symbol": "COLB"
            },
            {
              "symbol": "BLFS"
            },
            {
              "symbol": "DDOG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T11:25:34+00:00",
    "headline": "Novo’s Wegovy pill is planned to enter U.S. self-pay channels, Reuters says",
    "summary": "Novo Nordisk’s (NVO) newly approved version of Wegovy is planned to go straight to U.S. self-pay channels in early January, Maggie Fick of Reuters reports. As part of the company’s deal with the Trump administration in November, Novo and Lilly (LLY) agreed to sell starter doses of their weight-loss pills for $149 a month to U.S. Medicare and Medicaid patients as well as cash-paying customers without insurance coverage. The pill will serve as a test case for the cash-paying consumer market.Claim",
    "url": "https://finance.yahoo.com/news/novo-wegovy-pill-planned-enter-112534671.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "c37fe7b7-2775-33a4-a01b-2404c79d04d9",
      "content": {
        "id": "c37fe7b7-2775-33a4-a01b-2404c79d04d9",
        "contentType": "STORY",
        "title": "Novo’s Wegovy pill is planned to enter U.S. self-pay channels, Reuters says",
        "description": "",
        "summary": "Novo Nordisk’s (NVO) newly approved version of Wegovy is planned to go straight to U.S. self-pay channels in early January, Maggie Fick of Reuters reports. As part of the company’s deal with the Trump administration in November, Novo and Lilly (LLY) agreed to sell starter doses of their weight-loss pills for $149 a month to U.S. Medicare and Medicaid patients as well as cash-paying customers without insurance coverage. The pill will serve as a test case for the cash-paying consumer market.Claim",
        "pubDate": "2025-12-24T11:25:34Z",
        "displayTime": "2025-12-24T11:25:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/novos-wegovy-pill-is-planned-to-enter-u-s-self-pay-channels-reuters-says-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FTa8CtQV3vs7_S_EPzhwOA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KEvkicUgSm7sULbOJuMgBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-wegovy-pill-planned-enter-112534671.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-wegovy-pill-planned-enter-112534671.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T13:00:00+00:00",
    "headline": "Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage",
    "summary": "Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare and Medicaid Services (CMS) and pharmaceutical partners,...",
    "url": "https://finance.yahoo.com/news/obesity-medicine-association-releases-position-130000696.html",
    "source": "Newsfile",
    "provider": "yfinance",
    "raw": {
      "id": "7f5ee1a3-cf05-3d63-adc1-94389706829c",
      "content": {
        "id": "7f5ee1a3-cf05-3d63-adc1-94389706829c",
        "contentType": "STORY",
        "title": "Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage",
        "description": "",
        "summary": "Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare and Medicaid Services (CMS) and pharmaceutical partners,...",
        "pubDate": "2025-12-24T13:00:00Z",
        "displayTime": "2025-12-24T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/newsfile_64/7eb8e38b61c82ef10d1f9b42c1c6fbd8",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mlwOS5zNvgXtF3RPkOtqlw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/7eb8e38b61c82ef10d1f9b42c1c6fbd8.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8fvQ4kEh.AXtbuLuzi0gAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/7eb8e38b61c82ef10d1f9b42c1c6fbd8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Newsfile",
          "url": "https://www.newsfilecorp.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/obesity-medicine-association-releases-position-130000696.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/obesity-medicine-association-releases-position-130000696.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T15:49:00+00:00",
    "headline": "NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?",
    "summary": "NVO secures FDA approval for its first oral obesity pill, Wegovy, giving it a first-to-market edge and raising questions about Lilly's next move.",
    "url": "https://finance.yahoo.com/news/nvos-first-oral-obesity-pill-154900283.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8c4e07e4-1a88-338e-8b66-f25389da9c15",
      "content": {
        "id": "8c4e07e4-1a88-338e-8b66-f25389da9c15",
        "contentType": "STORY",
        "title": "NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?",
        "description": "",
        "summary": "NVO secures FDA approval for its first oral obesity pill, Wegovy, giving it a first-to-market edge and raising questions about Lilly's next move.",
        "pubDate": "2025-12-24T15:49:00Z",
        "displayTime": "2025-12-24T15:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WtA490SSyXq.BB5XEEYFSg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BdQSUWaJAMCKg7gp75c9jQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nvos-first-oral-obesity-pill-154900283.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nvos-first-oral-obesity-pill-154900283.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-24T22:46:26+00:00",
    "headline": "Weight-loss pill approval spurs food industry overhaul",
    "summary": "<body><p>STORY: Packaged food makers and fast-food chains could be forced to overhaul more of their products next year as a newly-approved weight-loss pill hits the market.</p><p>That's according to food industry analysts who spoke to Reuters.</p><p>The U.S. Food and Drug Administration approved Novo Nordisk's Wegovy GLP-1 pill on Monday, sending shares of food companies down on Tuesday.</p><p>Eli Lilly's rival medication is expected to gain approval from regulators next year.</p><p>Up until now, GLP-1 medications have only been available in injectible form.</p><p>More Americans are expected to try the drugs as a pill rather than as a shot because the medication will be cheaper and many patients are hesitant to inject themselves.</p><p>Food companies including Conagra Brands and Nestle are already dealing with shifts in consumer tastes toward higher protein and smaller portions due to the popularity of weight-loss injections.&nbsp;</p><p>Earlier this year, Conagra started labeling some of its Healthy Choice frozen meals with high protein and fiber as, quote, \"GLP-1 friendly.\"&nbsp;</p><p>Nestle, the world's biggest food company, has also introduced new frozen meals that cater specifically to GLP-1 users, called Vital Pursuit.&nbsp;</p><p>Some 40% of American adults are obese, U.S. government data shows, and around 12% of adults say they currently take GLP-1 drugs, according to a poll published last month by health policy research organization KFF.</p></body>",
    "url": "https://finance.yahoo.com/video/weight-loss-pill-approval-spurs-224626785.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "d646d17f-65d4-3c5b-943a-6814d905b8c6",
      "content": {
        "id": "d646d17f-65d4-3c5b-943a-6814d905b8c6",
        "contentType": "VIDEO",
        "title": "Weight-loss pill approval spurs food industry overhaul",
        "description": "<title><body><p>STORY: Packaged food makers and fast-food chains could be forced to overhaul more of their products next year as a newly-approved weight-loss pill hits the market.</p><p>That's according to food industry analysts who spoke to Reuters.</p><p>The U.S. Food and Drug Administration approved Novo Nordisk's Wegovy GLP-1 pill on Monday, sending shares of food companies down on Tuesday.</p><p>Eli Lilly's rival medication is expected to gain approval from regulators next year.</p><p>Up until now, GLP-1 medications have only been available in injectible form.</p><p>More Americans are expected to try the drugs as a pill rather than as a shot because the medication will be cheaper and many patients are hesitant to inject themselves.</p><p>Food companies including Conagra Brands and Nestle are already dealing with shifts in consumer tastes toward higher protein and smaller portions due to the popularity of weight-loss injections. </p><p>Earlier this year, Conagra started labeling some of its Healthy Choice frozen meals with high protein and fiber as, quote, \"GLP-1 friendly.\" </p><p>Nestle, the world's biggest food company, has also introduced new frozen meals that cater specifically to GLP-1 users, called Vital Pursuit. </p><p>Some 40% of American adults are obese, U.S. government data shows, and around 12% of adults say they currently take GLP-1 drugs, according to a poll published last month by health policy research organization KFF.</p></body></title>",
        "summary": "<body><p>STORY: Packaged food makers and fast-food chains could be forced to overhaul more of their products next year as a newly-approved weight-loss pill hits the market.</p><p>That's according to food industry analysts who spoke to Reuters.</p><p>The U.S. Food and Drug Administration approved Novo Nordisk's Wegovy GLP-1 pill on Monday, sending shares of food companies down on Tuesday.</p><p>Eli Lilly's rival medication is expected to gain approval from regulators next year.</p><p>Up until now, GLP-1 medications have only been available in injectible form.</p><p>More Americans are expected to try the drugs as a pill rather than as a shot because the medication will be cheaper and many patients are hesitant to inject themselves.</p><p>Food companies including Conagra Brands and Nestle are already dealing with shifts in consumer tastes toward higher protein and smaller portions due to the popularity of weight-loss injections.&nbsp;</p><p>Earlier this year, Conagra started labeling some of its Healthy Choice frozen meals with high protein and fiber as, quote, \"GLP-1 friendly.\"&nbsp;</p><p>Nestle, the world's biggest food company, has also introduced new frozen meals that cater specifically to GLP-1 users, called Vital Pursuit.&nbsp;</p><p>Some 40% of American adults are obese, U.S. government data shows, and around 12% of adults say they currently take GLP-1 drugs, according to a poll published last month by health policy research organization KFF.</p></body>",
        "pubDate": "2025-12-24T22:46:26Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/w0vtQcB.rZFJjC9OXVGG0A--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/1fc41f78-8369-4cf5-a84a-f963ac6d0b46/main/1280x720/52s430ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Lk92vEuHL6lvCuYauOPug--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/1fc41f78-8369-4cf5-a84a-f963ac6d0b46/main/1280x720/52s430ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hNO.k4ZT3_8njg_lTA8lhw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/1fc41f78-8369-4cf5-a84a-f963ac6d0b46/main/1280x720/52s430ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/weight-loss-pill-approval-spurs-224626785.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/weight-loss-pill-approval-spurs-224626785.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NSRGF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "CAG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]